Does the injection site matter for MT-1
For patients who have resolved their diabetes using a GLP-1 for weight loss and glucose control, they may have a return of their type 2 diabetes, says Lofton, who adds that it varies from person to person
"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies." Diabetes, Obesity and Metabolism
doi:10.1056/nejmoa2504214 11.A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
[1] The mechanism of action centres on mimicking the naturally occurring hormone GLP-1, which is released from the intestine in response to food intake
Key among them is the word obesity. While it is the scientifically correct name for a disease and a common clinical term, NPF acknowledges that this word is triggering and problematic, and it is used only for the clearest of accuracy